Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Sep 23;385(13):1244-1246.
doi: 10.1056/NEJMc2111462. Epub 2021 Aug 11.

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients

Victoria G Hall  1 , Victor H Ferreira  1 , Terrance Ku  1 , Matthew Ierullo  1 , Beata Majchrzak-Kita  1 , Cecilia Chaparro  1 , Nazia Selzner  1 , Jeffrey Schiff  1 , Michael McDonald  1 , George Tomlinson  1 , Vathany Kulasingam  1 , Deepali Kumar  1 , Atul Humar  1
Affiliations
Randomized Controlled Trial

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients

Victoria G Hall et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Immune Responses in Transplant Recipients Who Received a Third Dose of mRNA-1273 or Placebo.
Panel A shows the anti–receptor-binding domain (RBD) antibody levels in the mRNA-1273 group (60 patients) and the placebo group (57 patients) after the third dose. Each point represents an individual patient, and horizontal lines indicate the median. The dotted line indicates the threshold value of 100 U per milliliter. Values below the detection limit are plotted as 0.2 U per milliliter. The relative risk of being above the threshold in the mRNA-1273 group as compared with the placebo group was 3.1 (95% confidence interval [CI], 1.7 to 5.8; P<0.001). Panel B shows the anti-RBD antibody levels before and after the third dose. Panel C shows box-and-whisker plots of the percent neutralization before and after the third dose. The whiskers indicate the range, the top and bottom of the boxes indicate the interquartile range, and the horizontal line within each box indicates the median. The dotted line indicates the 30% threshold for neutralizing antibody positivity. For percent neutralization, the 95% CI for the between-group difference was 11 to 76 percentage points. The relative risk of being above the 30% threshold in the mRNA-1273 group as compared with the placebo group was 2.4 (95% CI, 1.5 to 4.0). Panel D shows the polyfunctional CD4+ T-cell response (i.e., cells producing both interleukin-2 and interferon-γ) before and after the third dose in the mRNA-1273 group (34 patients) and the placebo group (31 patients). Horizontal lines indicate the median (95% CI for the between-group difference, 46 to 986). The widths of the confidence intervals have not been adjusted for multiplicity and cannot be used to infer treatment effects for secondary end points.
See this image and copyright information in PMC

Comment in

  • doi: 10.1056/NEJMe2112866

References

    1. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021;325:2204-2206. - PMC - PubMed
    1. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med 2021;385:661-662. - PMC - PubMed
    1. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 2021;590:630-634. - PMC - PubMed
    1. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27:1205-1211. - PubMed
    1. Turner JS, O’Halloran JA, Kalaidina E, et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 2021. June 28 (Epub ahead of print). - PMC - PubMed

Publication types

MeSH terms